Vitamin D3 suppresses the androgen-stimulated growth of mouse mammary carcinoma SC-3 cells by transcriptional repression of fibroblast growth factor 8

Journal of Cellular Physiology

Volumn 207, Issue 3, 2006, Pages 793-799

  Kawata, Hirotoshi ^a   Kamiakito, Tomoko ^a   Takayashiki, Norio ^a   Tanaka, Akira ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANDROGEN; ANDROGEN RECEPTOR; CALCITRIOL; COLECALCIFEROL; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FIBROBLAST GROWTH FACTOR 8; GROWTH INHIBITOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P15; RETINOIC ACID; RETINOL; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; GENE REPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE;

ANDROGENS; ANIMALS; BREAST NEOPLASMS; CELL LINE; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CHOLECALCIFEROL; DOWN-REGULATION; FIBROBLAST GROWTH FACTOR 8; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY GLANDS, ANIMAL; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; TRETINOIN;

ANIMALIA;

EID: 33646382580     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20618     Document Type: Article

References (18)

1. Blutt SE, Weigel NL. 1999. Vitamin D and prostate cancer. Proc Soc Exp Biol Med 221:89-98.
2. Blutt SE, Mcdonnell TJ, Polek TC, Weigel NL. 2000. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17.
3. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15-27.
4. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. 1999. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 18:2755-2761.
5. Feldman D, Zhao X-Y, Krishnan AV. 2000. Vitamin D and prostate cancer. Endocrinology 141:5-9.
6. Glass CK, Rosenfeld MG. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141.
7. Huang YC, Chen JF, Hung WC. 2004. Vitamin D3 receptor/Sp1 complex required for the induction of p27/Kip1 expression by vitamin D3. Oncogene 23:4856-4886.
8. Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H, Koeffler HP. 2005. CCAAT/enhancer-binding protein delta: A molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res 65:4762-4768.
9. Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, Gomm JJ, Coombes RC, Johnston CL. 1999. Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 18:1053-1060.
10. 3 inducible transcription factor and its role in the vitamin D action. Endocr Regul 38: 29-38.
11. Peehl DM, Krishnan AV, Feldman D. 2003. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 133:24613-24693.
12. Simeone AM, Tari AM. 2004. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 61:1475-1484.
13. Takayashiki N, Kawata H, Kamiakito T, Tanaka A. 2005. Transcriptional repression of fibroblast growth factor 8 by transforming growth factor-β in androgen-dependent SC-3 cells. J Steroid Biochem Mol Biol 96:1-12.
14. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K. 1992. Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci 89:8928-8932.
15. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M, Fukayama M. 1998. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res 58:2053-2056.
16. 3 receptor. J Biol Chem 273:10338-10348.
17. Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Härkönen PL. 2001. Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest 81:815-826.
18. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent Gl accumulation. Endocrinology 139:1197-1207.